NCT03920514

Brief Summary

to determine the most suitable time for administration of (human chorionic gonadotropin )hCG prior to intrauterine insemination (IUI) to optimize pregnancy outcome and to have the best success rates so the cases divided in to four groups according to the time of hCG administration .

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
80

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Apr 2019

Shorter than P25 for phase_4

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 16, 2019

Completed
3 days until next milestone

First Posted

Study publicly available on registry

April 19, 2019

Completed
11 days until next milestone

Study Start

First participant enrolled

April 30, 2019

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2019

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2019

Completed
Last Updated

April 19, 2019

Status Verified

April 1, 2019

Enrollment Period

5 months

First QC Date

April 16, 2019

Last Update Submit

April 17, 2019

Conditions

Keywords

infertility

Outcome Measures

Primary Outcomes (2)

  • Primary outcome

    Positive serum beta hCG test

    14 days after IUI

  • Secondary outcome

    Clinical pregnancy defined as prescence of at least one Intrauterine gestational sac with fetal pole on Transvaginal scan

    4 weeks after insemination

Study Arms (4)

GROUP 1

ACTIVE COMPARATOR

IUI 24 hours after hCGadminstration

Drug: hCG

GROUP 2

ACTIVE COMPARATOR

IUI 36 hours after hCG adminstration

Drug: hCG

GROUP 3

ACTIVE COMPARATOR

IUI 48 hours after hCG adminstration

Drug: hCG

GROUP 4

ACTIVE COMPARATOR

IUI at time of hCG adminstration

Drug: hCG

Interventions

hCGDRUG

Women will be given hCG before or with IUI

Also known as: Pregnyl
GROUP 1GROUP 2GROUP 3GROUP 4

Eligibility Criteria

Age18 Years - 40 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Mild male infertility or unexplained infertility

You may not qualify if:

  • Adanced male factor endometriosis uterine abnormality sever semen parameters i impairment according to WHO 2010 non ovulatory cycles bilatral tubal block

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (3)

  • Aydin Y, Hassa H, Oge T, Tokgoz VY. A randomized study of simultaneous hCG administration with intrauterine insemination in stimulated cycles. Eur J Obstet Gynecol Reprod Biol. 2013 Oct;170(2):444-8. doi: 10.1016/j.ejogrb.2013.07.022. Epub 2013 Aug 6.

    PMID: 23932307BACKGROUND
  • Cantineau AE, Janssen MJ, Cohlen BJ, Allersma T. Synchronised approach for intrauterine insemination in subfertile couples. Cochrane Database Syst Rev. 2014 Dec 21;2014(12):CD006942. doi: 10.1002/14651858.CD006942.pub3.

    PMID: 25528596BACKGROUND
  • Yumusak OH, Kahyaoglu S, Pekcan MK, Isci E, Cinar M, Tasci Y. Does intrauterine insemination timing matter for achieving pregnancy during ovulation induction using gonadotropins? A retrospective cohort study. J Chin Med Assoc. 2017 Jun;80(6):366-370. doi: 10.1016/j.jcma.2016.06.005. Epub 2016 Sep 27.

    PMID: 27686502BACKGROUND

MeSH Terms

Conditions

Infertility

Interventions

Chorionic Gonadotropin

Condition Hierarchy (Ancestors)

Genital DiseasesUrogenital Diseases

Intervention Hierarchy (Ancestors)

GonadotropinsPeptide HormonesHormonesHormones, Hormone Substitutes, and Hormone AntagonistsPlacental HormonesPeptidesAmino Acids, Peptides, and ProteinsPregnancy ProteinsProteins

Study Officials

  • Allam Mohamed Abd elmonam, Professor of obs and gyn

    Faculty of medicine sohag university

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Salwa Sabry Ahmed, Candidate

CONTACT

Mohamed Sabry Ebrahim, Lecture of obs and gyn

CONTACT

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
INVESTIGATOR
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Model Details: Women will be randomly divided in to four groups the first Group will undergo IUI after 24 H of hCG administration the second g will undergo IUI after 36 h after hCG the third Group will undergo IUI after 48h of hCG administration the last Group will undergo IUI at the time of hCG adminstration
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Faculty of medicine sohag university

Study Record Dates

First Submitted

April 16, 2019

First Posted

April 19, 2019

Study Start

April 30, 2019

Primary Completion

September 30, 2019

Study Completion

December 31, 2019

Last Updated

April 19, 2019

Record last verified: 2019-04